Screener
CapEx at other companies
Other financials
Where this comes from
Reported directly by Eton Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.
The source filing: Eton Pharmaceuticals, Inc.’s 10-Q, filed May 14, 2026.
- Filed
- May 14, 2026, 4:17 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001437749-26-017064
| Line item | Three months ended / March 31, 2026 | Three months ended / March 31, 2025 |
|---|---|---|
| Net cash from operating activities | 7,405 | 2,090 |
| Cash flows used in investing activities | ||
| Purchases of product license rights | (15,000) | — |
| Purchases of property and equipment | (75) | — |
| Net cash used in investing activities | (15,075) | — |
| Cash flows from financing activities | ||
| Proceeds from stock option exercises | 1,389 | 394 |
| Net cash from financing activities | 1,389 | 394 |
Document
FAQ
- What is Eton Pharmaceuticals, Inc.'s capex?
- Eton Pharmaceuticals, Inc. (ETON) reported capex of $75K in Q1 2026.
- What is the long-term trend for Eton Pharmaceuticals, Inc.'s capex?
- Over 2 years (2022 to 2025), Eton Pharmaceuticals, Inc.'s capex has grown at a 196.0% compound annual growth rate (CAGR), from $38K to $333K.
- What does capex mean?
- Cash spent on property, plant, and equipment — the primary measure of investment in productive capacity and infrastructure.
Ask your AI about Eton Pharmaceuticals, Inc.'s capex.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude